I(2),4-Dihydroxy-I+/--oxobenzenepropanoic acid | 959235-80-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: I(2),4-Dihydroxy-I+/--oxobenzenepropanoic acid
• 英文别名: 3-hydroxy-3-(4-hydroxyphenyl)-2-oxopropanoic acid
• CAS: 959235-80-4
• 化学式: C₉H₈O₅
• 分子量: 196.16
• InChiKey: BDOXXTZHQOCVOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  94.8
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Compositions and methods of using D-DOPA to treat Parkinson's disease
  申请人：Karoum Farouk

  公开号：US20060241183A1

  公开（公告）日：2006-10-26

  A method of treating Parkinson's disease by administering the racemic mixture of D,L-DOPA in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease. Alternatively, D-DOPA is administered in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease.

  一种治疗帕金森病的方法，通过将D,L-DOPA的外消旋混合物与外周氨基酸脱羧酶和儿茶酚、O-甲基转移酶（COMT）抑制剂以药学上可接受的盐形式和有效剂量联合给药来治疗帕金森病。或者，D-DOPA与外周氨基酸脱羧酶和儿茶酚-O-甲基转移酶（COMT）抑制剂以药学上可接受的盐形式和有效剂量联合给药，用于治疗帕金森病。
• JPS62289194A
  申请人：——

  公开号：JPS62289194A

  公开（公告）日：1987-12-16
• [EN] COMPOSITIONS AND METHODS OF USING D-DOPA TO TREAT PARKINSON'S DISEASE<br/>[FR] COMPOSITIONS ET PROCEDES D'UTILISATION DE D-DOPA POUR TRAITER LA MALADIE DE PARKINSON
  申请人：KAROUM FAROUK

  公开号：WO2006037061A2

  公开（公告）日：2006-04-06

  A method of treating Parkinson's disease by administering the racemic mixture of D,L-DOPA in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease. Alternatively, D-DOPA is administered in combination with both peripheral amino acid decarboxylase and catechol, O-methyltransferase (COMT) inhibitors in pharmaceutically acceptable salts forms and effective doses for the treatment of Parkinson's disease.